MAY 28, 2020 10:00 AM PDT

In situ immune profiling of heart transplant biopsies improves diagnostic accuracy and rejection risk stratification

Sponsored by: Akoya Biosciences
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Physician, Advanced Heart Failure and Transplant Medicine, University of Pennsylvania
    Biography
      My research focuses on applying computer-assisted analytical methods to multidimensional diagnostic data in order to enhance the understanding of human cardiovascular disease. With clinical training in cardiovascular medicine and scientific training in translational research, my research aims to identify appropriate populations and experimental designs for introducing innovative diagnostic and analytical approaches into clinical care.

      Specific areas of interest include computational morphologic analysis of human heart tissue, in-situ molecular diagnostics, and comprehensive characterizations of the role of inflammation and immune cell populations in diseases of the cardiovascular systems. In recent years, I have participated in research characterizing inflammatory markers and immune cell signatures in diseases of the heart and vasculature. I have served as a co-investigator on a prospective clinical trial investigating a targeted tissue sampling and advanced tissue characterization in patients with new- and recent-onset cardiomyopathy. I have also led multiple projects using machine learning computer-vision technologies to identify quantitative morphologic features which strongly predict important patient outcomes in native and transplanted heart tissue samples. My goal is to integrate automated morpho-molecular analysis pipelines with genomic and transcriptomic data to improve prediction and biological characterization of important patient outcomes.

    Abstract
    DATE:  May 28, 2020
    TIME:   10:00am PT, 1:00pm ET
     
    Cardiac allograft rejection is a serious concern in transplant medicine, conferring an increased risk of acute graft failure and adverse patient outcomes. The guideline-directed histologic grading of biopsy tissues for rejection surveillance has modest diagnostic performance, correlating poorly with the clinical trajectory of concurrent rejection events and offering minimal information about future rejection risk. These limitations expose patients to an immediate potential risk of over- or under-treating for rejection, while also imposing a rigid, protocolized rejection surveillance and immunosuppression weaning strategy that appears outdated in an era of precision medicine.
     
    These findings highlight the limitations of the current guideline-recommended biopsy grading standard, while supporting the diagnostic and prognostic importance of the PD1/PD-L1 checkpoint system and regulatory T-cells in cardiac allografts. We believe that the results of this proof-of-concept work will lead to a rethinking of rejection surveillance protocols for heart transplant patients, and may represent an initial step towards identifying molecular targets for immunotherapeutics in transplant medicine.
     
     
    Learning Objectives:
    • Outline the limitations of conventional histologic rejection grading in heart transplant medicine, and how this affects patient outcomes.
    • Outline the potential of in-situ immune-phenotyping for improving diagnostic accuracy and rejection risk stratification.

     

     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources